FAP-2286 PET Imaging for Fibrosis

Palo Alto (17 mi)

Overseen byThomas A Hope, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Thomas Hope

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial uses a special imaging agent to detect scarring in the liver, lungs, and heart. It targets patients with these specific types of scarring because traditional imaging might not be as effective. The agent works by binding to a protein found in scarred tissues, making them visible on a PET scan.

Eligibility Criteria

This trial is for adults with confirmed pathologic fibrosis affecting the liver, lungs, or heart. Participants must understand and sign a consent form. It's not suitable for pregnant individuals or those unlikely to follow the trial procedures.

Treatment Details

The study tests a new imaging agent called 68Ga-FAP-2286 using PET scans to detect fibrosis in the liver, lungs, and heart. The agent binds to proteins that are more common in these types of fibrosis.

3Treatment groups

Experimental Treatment

Group I: Cohort 3: Myocardial FibrosisExperimental Treatment2 Interventions

Patients with myocardial fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.

Group II: Cohort 2: Pulmonary FibrosisExperimental Treatment2 Interventions

Patients with pulmonary fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.

Group III: Cohort 1: Liver FibrosisExperimental Treatment2 Interventions

Patients with liver fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.